Navigation Links
Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
Date:4/19/2011

ury and endothelial dysfunction, including models that are insensitive to aspirin.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.

About Cumberland Emerging Technologies

Cumberland Emerging Technologies, Inc. (CET) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc. and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at research centers to the commercial marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure for its own product development activities as well as for other early-stage life sciences companies.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future eve
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... 28, 2015 Zimmer Holdings, Inc. (NYSE and ... agreements with buyers to divest in the ... System assets, Biomet Discovery® Elbow System assets and Cobalt™ ... of Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... work constructively with the Bureau of Competition Staff of ...
(Date:5/28/2015)... , May 28, 2015  Maetrics ( http://maetrics.com ), ... sciences sector, wrapped up a successful conference, "The cost ... Technology industry," today in Zurich . ... ) and its Switzerland -based team, ... the Medical Technology field to an exclusive local audience. ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2
... 23, 2012  Edgemont Pharmaceuticals, LLC, a neuroscience focused ... now available by prescription nationwide. This is the ... single-dose tablet. The U.S. Food and Drug Administration ... its fluoxetine tablets in October 2011. ...
... Israel, Jan. 23, 2012 InspireMD, Inc. (OTC BB: ... focusing on the development and commercialization of its proprietary ... Myocardial Infarctions, today announced its business objectives for 2012 ... based on the Company,s proprietary MicroNet™ platform technology. ...
Cached Medicine Technology:Edgemont - New Fluoxetine Tablets, 60 mg Now Available 2Edgemont - New Fluoxetine Tablets, 60 mg Now Available 3Edgemont - New Fluoxetine Tablets, 60 mg Now Available 4Edgemont - New Fluoxetine Tablets, 60 mg Now Available 5Edgemont - New Fluoxetine Tablets, 60 mg Now Available 6InspireMD Provides Corporate Update, Plans for 2012 2InspireMD Provides Corporate Update, Plans for 2012 3InspireMD Provides Corporate Update, Plans for 2012 4InspireMD Provides Corporate Update, Plans for 2012 5InspireMD Provides Corporate Update, Plans for 2012 6
(Date:5/30/2015)... May 30, 2015 Promising clinical trial ... (ASCO) Annual Meeting 2015 show activity of the investigational ... case specifically against brain metastases and in another case ... patients. , "I am thrilled to have been able ... early 40s. She didn't have any other great treatment ...
(Date:5/30/2015)... The results of a 40+ year ... high potential to cause mesothelioma, regardless of the volume ... on the Surviving Mesothelioma website. , The study ... Lodz, Poland found that, among the 138 cases of ... 2012, all of them happened at plants that had, ...
(Date:5/30/2015)... New York (PRWEB) May 30, 2015 ... pay $100 million in punitive and compensatory damages ... plaintiff who suffered serious complications following implantation of ... to a verdict rendered on May 28th in ... million in compensatory damages after the jury found ...
(Date:5/30/2015)... of Industry, CA (PRWEB) May 30, 2015 ... best-in-class technology and foreign travelers who experienced OGAWA products ... available in the U.S. , A leader in ... OGAWA is a cutting-edge designer, researcher, developer and manufacturer ... the longevity and superior craftsmanship of their products, health ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 The ... Services in coordination with ONEgeneration Senior Enrichment Center, headed ... Manager Raymond de Guzman and Brain Fitness Program Director ... joined this event learned that there are many ways ... Tee Bar showed the residents the different ways to ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3
... Nov. 4 (HealthDay News) -- Many smokers in the United ... as snuff and chew tobacco, a combination that makes quitting ... analyzed data from the 2009 Behavioral Risk Factor Surveillance System ... smokeless tobacco ranged from 0.9 percent in Puerto Rico to ...
... A patient with a long head biceps (LHB) tendinopathy, ... may also have a shoulder problem and/or a rotator ... trauma, overuse, inflammation or degeneration. Because of the ... severity, a patient needs a thorough examination, including radiographic ...
... THURSDAY, Nov. 4 (HealthDay News) -- Babies are born ... including one linked to introspection, a new study shows. ... development and activity. Scientists at the MRC Clinical ... to examine the brains of 70 babies born at ...
... 3 (HealthDay News) -- Friendly discussions with other people can ... competitive in tone aren,t helpful, finds a new study. ... way you do when you,re making friends, can provide mental ... the Institute for Social Research at the University of Michigan, ...
... less healthy than their English counterparts, but they live as long ... study by researchers from the RAND Corporation and the Institute for ... 55 to 64 have higher rates of chronic diseases than ... And Americans age 65 and older -- while still sicker than ...
... Edith P. Mitchell, M.D., clinical professor, Department of ... Jefferson University, and associate director of Diversity Programs ... recently named ,Physician of the Year, by CancerCare, ... support services to anyone affected by cancer: people ...
Cached Medicine News:Health News:Smokeless Tobacco Use Widespread in Some States 2Health News:Brain May Be More Developed at Birth Than Thought 2Health News:Good Conversation Can Boost Brain Power, Study Finds 2Health News:Americans less healthy than English, but live as long or longer, study finds 2Health News:Americans less healthy than English, but live as long or longer, study finds 3Health News:CancerCare names Jefferson professor Physician of the Year 2
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... The ADVIA 1650 has minimal requirements for ... reagent consumption (as low as 80 L/test) ... maximizing management efficiency. , , Outstanding productivity ... throughput of up to 1650 tests/hour provide ...
... Every day you face key challenges. Reducing ... more complex laboratory workload. Meeting ever-increasing expectations ... laboratory quality while dealing with labor shortages. ... of patient care. Now theres targeted relief ...
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
Medicine Products: